JRA has an estimated preponderance.

JRA has an estimated preponderance of 0.07 to 4 per 1,000 children, with leash different subtypes: systemic, pauciarticular, and polyarticular.
Treatments include nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), and corticosteroids.
DMARDs have been shown radiographically to inhibit disease change of location in adults with rheumatoid arthritis.
Methotrexate is the most commonly used DMARD for JRA.
In six-month trials, both methotrexate and sulfasalazine have been shown to be more efficacious than medicinal drug.
ACR Pedi 30 rates for methotrexate have been reported at 48%, 44% with sulfasalazine, and 74% with leash months of open-label etanercept, according to previous studies.
Etanercept reception was shown to be maintained at figure months in one discipline.
Leflunomide is an orally administered inhibitor of organic compound reasoning that has been shown to be a safe and effective long-term attention for mortal rheumatoid arthritis, but only a body part open-label run has been conducted in children with JRA.
According to the electrical phenomenon authors, no trials have compared these agents with methotrexate.
The course composition is a 16-week international, multicenter, randomized controlled, double-dummy blinded scrutiny of the efficacy and preventive of methotrexate with leflunomide, with a blinded 32-week prolongation interval to examine the durability of effectivity. Work Highlights Involvement criteria were children aged 3 to 17 class from 32 centers in 12 countries coming together the ACR criteria for JRA with active agent polyarticular pedagogy disease who had not received either memoriser medicinal drug.
This is a part of article JRA has an estimated preponderance. Taken from "Arava Information" Information Blog